In a recent filing with the Securities and Exchange Commission, it was disclosed that Tomas Orozco, Executive Vice President of Consumer Care at NeueHealth, Inc. (NASDAQ:NEUE), sold a portion of his holdings in the company. The transaction, dated January 6, 2025, involved the sale of 1,233 shares of common stock at a weighted average price of $7.33 per share, resulting in a total transaction value of approximately $9,037. According to InvestingPro data, the stock has shown strong momentum with a 44% gain over the past six months, though it remains significantly below its 52-week high of $16.59.
The shares were sold to cover tax withholding obligations following the vesting of restricted stock units. This transaction was not discretionary, as noted in the filing. Following this sale, Orozco retains ownership of 7,830 shares in the company. InvestingPro analysis indicates the company currently trades below its Fair Value, with 12 additional investment insights available to subscribers.
NeueHealth, Inc., previously known as Bright Health Group Inc (NYSE:NEUE)., operates in the hospital and medical service plans industry. The company is headquartered in Doral, Florida. The company reported revenue of $997 million in the last twelve months, though analysts anticipate sales decline in the current year.
In other recent news, RBC Capital has revised its price target for NeueHealth from $8.00 to $7.00, maintaining a Sector Perform rating on the company's stock. This adjustment comes in the wake of the company's third-quarter results, which surpassed expectations despite a year-over-year revenue decline of 9.01%. The company's current ratio, a key liquidity indicator, stands at a concerning 0.68, although the management has confirmed that their guidance remains unchanged.
RBC Capital's new price target reflects an updated valuation model for NeueHealth, taking into account its third-quarter performance and aligning the valuation with the upcoming fiscal period. The firm's Sector Perform rating suggests a neutral stance on NeueHealth's stock, predicting it will perform in line with sector expectations.
Investors can consider this revised price target and rating in their evaluation of NeueHealth's stock for portfolio inclusion. According to InvestingPro analysis, the stock appears undervalued at current levels. These are among the latest developments for the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.